KIT and acute myeloid leukemia: However, it has been demonstrated that targeting CD117 with a CD117‐blocking antibody may not be sufficient to fully eliminate all LICs and to achieve high donor cell chimerism after HSCT.15 16 Therefore, novel anti-CD117 antibody-drug conjugates,17 18 anti-CD117 chimeric antigen receptor cells-T (CAR-T),19, 21 a CD117-targeting bispecific antibody22 and CD117 epitope-edited donor HSCs in combination with anti-CD117 CAR-T cells have been explored for improved targeting of acute myeloid leukemia (AML).23